Mission Therapeutics wins ‘One to Watch’ Private UK Life Science Company of the Year

CAMBRIDGE, UK – 7 September 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, is pleased to announce it has won the “One to Watch Private UK Life Science Company of the Year” Award at the Biotech & Money 2016 Awards Dinner.

Dr Anker Lundemose, CEO of Mission Therapeutics, said: “We are very pleased to have been recognized as the “One to Watch Private UK Life Science Company of the Year” Award, voted for by a highly experienced judging panel, as well as participants from the life science community. This has been a transformational year for Mission Therapeutics. Our recent fundraise supported by high profile investors is a strong endorsement of Mission’s unique discovery platform and will enable us to execute the company’s strategy by advancing our pipeline programmes through early clinical development.”

Held in London at the historical Gibson Hall, the inaugural Biotech & Money 2016 Awards Dinner was attended by over 250 C-Suite executives, investors, key stakeholders and KOLs in the sector.

For more information:


Mission Therapeutics Ltd

Anker Lundemose

Chief Executive Officer

Tel +44 1223 497199

Hume Brophy

Mary Clark, Eva Haas, Hollie Vile

Email: missiontherapeutics@humebrophy.com

Tel: +44 20 7862 6390


About Mission Therapeutics

Mission Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.

Mission’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of Mission and is the Chief Scientific Officer of the Company.

Mission Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.